For the study, researchers reviewed 14 previous C. diff studies conducted prior to August 2016. Elements of C. diff examined in the study included treatment cost, cure rates and infection recurrence rates, among other influential treatment cost factors.
Here are four study findings.
1. Fidaxomicin, a newer treatment for C. diff, was often the most cost-effective treatment, though the findings were not definitive, as results from the individual studies largely varied based on the nature of the infection.
2. For initial C. diff, treatment with fidaxomicin was more cost-effective than vancomycin or metronidazole in 2 of 3 studies.
3. For more severe initial C. diff, fidaxomicin was the most cost-effective in 2 of 3 studies. For recurrent C. diff infections, fidaxomicin proved most cost-effective in 3 of 5 studies.
4. However, researchers found fecal microbiota transplantation via colonoscopy to be most cost-effective in treating recurrent C. diff in 4 out of 4 studies.
“The cost-effectiveness of fidaxomicin compared with other pharmacologic therapies was not definitive for either initial or recurrent [C. diff],” wrote the study’s authors. “Despite its high cost, FMT by colonoscopy may be a cost-effective therapy for recurrent [C. diff]. A consensus on model design and assumptions are necessary for future comparison of [C. diff] treatment.”
More articles on infection control:
This Seattle hospital aims to get sepsis patients on antibiotics within 3 hours — here’s how
How one hospital’s 60-second test prevents pediatric flu, sepsis deaths
Flu activity remains elevated, pediatric deaths near 100: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.